SAFB1 interacts with and suppresses the transcriptional activity of p53  by Peidis, Philippos et al.
FEBS Letters 585 (2011) 78–84journal homepage: www.FEBSLetters .orgSAFB1 interacts with and suppresses the transcriptional activity of p53
Philippos Peidis a,1,2, Nikolaos Voukkalis a,1, Eleni Aggelidou b, Eleni Georgatsou c,
Margarita Hadzopoulou-Cladaras b, Robert E. Scott d, Eleni Nikolakaki a, Thomas Giannakouros a,⇑
a Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
b Laboratory of Developmental Biology, Department of Biology, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
c Laboratory of Biochemistry, Department of Medicine, School of Health Sciences, University of Thessaly, Mezourlo, Larissa 41110, Greece
dVarigenix Inc., Memphis, TN 38120, USA
a r t i c l e i n f oArticle history:
Received 26 July 2010
Revised 23 November 2010
Accepted 24 November 2010
Available online 3 December 2010
Edited by Varda Rotter
Keywords:
Scaffold Attachment Factor B1
p53
SRPK1a
Nuclear matrix
Transcription regulation0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.11.054
⇑ Corresponding author.
E-mail address: giannako@chem.auth.gr (T. Gianna
1 These authors contributed equally to this study.
2 Present address: Lady Davis Institute for Medical R
Mortimer B. Davis-Jewish General Hospital, Montreal,a b s t r a c t
A signiﬁcant amount of nuclear p53 is found associated with the nuclear matrix in cells that were
exposed to genotoxic stress. In this study we identiﬁed Scaffold attachment factor B1 (SAFB1), a
nuclear matrix-associated protein that binds the scaffold or matrix attachment regions (S/MARs)
of genomic DNA, as a novel p53-interacting protein. SAFB1 was able to associate with p53 through
its C-terminal domain, while signiﬁcant co-localization of the two proteins was observed in cells
treated with 5-ﬂuorouracil or mithramycin. Binding of p53 to SAFB1 had a signiﬁcant functional
outcome, since SAFB1 was shown to suppress p53-mediated reporter gene expression. These data
suggest that nuclear matrix-associated proteins may play a critical role in regulating p53 localiza-
tion and activity.
Structured summary:
p53 physically interacts with SRPK1a: shown by two hybrid (view interaction)
p53 physically interacts with SRPK1a: shown by pull down (view interaction)
p53 physically interacts with SRPK1a: shown by anti bait coimmunoprecipitation (view interaction)
p53 physically interacts with SRPK1a: shown by anti tag coimmunoprecipitation (view interaction)
SAFB1 physically interacts with p53: shown by pull down (view interactions 1, 2)
SAFB1 physically interacts with p53: shown by anti bait coimmunoprecipitation (view interactions 1, 2)
SAFB1 and p53 colocalize: shown by ﬂuorescence microscopy (view interaction)
SAFB2 physically interacts with p53: shown by pull down (view interaction)
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The tumour suppressor p53 is amultifunctional protein,which in
response to diverse cellular stresses regulates target genes that in-
duce cell cycle arrest, apoptosis, senescence, DNA repair, or changes
in metabolism [1,2]. Notably, excess p53 activity is accompanied by
unwanted effects [3]. Thus, tight regulation of p53 is essential for
maintaining normal cell growth and preventing tumorigenesis.
Under normal conditions of growth, a small fraction of nuclear
p53 was found associated with the nuclear matrix both in primary
cultures of normal mammalian cells as well as in transformed cell
lines [4,5]. The structural basis and function of nuclear matrix-chemical Societies. Published by E
kouros).
esearch, McGill University, Sir
Quebec, Canada H3T 1E2.bound p53 are poorly understood. Interestingly, nuclear matrix-
bound p53 was shown to increase signiﬁcantly following exposure
of cells to genotoxic stress [5]. Furthermore, matrix association was
also observed in certain transformed cell lines expressing endoge-
nous mutants of p53, indicating that wild-type conformational
structure of p53 is not required for binding to the nuclearmatrix [5].
Scaffold attachment factor B1 [SAFB1; also known as HET
(Hsp27-ERE-TATA-binding protein) or HAP (hnRNP A1-associated
protein)] was originally isolated on the basis of its ability to bind
the scaffold or matrix attachment regions (S/MARs) of genomic
DNA [6]. These DNA elements, which usually comprise AT-rich
sequences, are thought to modulate gene expression through the
compartmentalization of chromatin into topologically separated
loops [7]. SAFB1 contains several domains, such as a SAF-box
(aa 35–67), an RNA recognition motif (RRM, aa 409–482), a nuclear
localization signal (NLS, aa 599–614), a Glu/Arg-rich region
(aa 619–699) and a Gly-rich region (aa 785–899) that have
been shown to interact with transcription and pre-mRNA
processing components, thereby mediating the assembly of variouslsevier B.V. All rights reserved.
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nuclear matrix [8–10]. Transcriptional repression seems to be the
most prominent function of SAFB1. While SAFB1 was initially
reported to repress estrogen-dependent transcription [11] recent
studies suggest that it may function as a more general transcrip-
tional repressor,mediating repressionmainly of immune regulators
and apoptotic genes [12,13].
In the present study we established that a fraction of nuclear
p53 binds to and co-localizes with SAFB1 in cells treated with
chemotherapeutic drugs. Binding of p53 to SAFB1 was shown to
be functionally signiﬁcant, since SAFB1 suppressed p53-mediated
reporter gene expression in p53-null cells (K562). In addition,
knock-down of SAFB1 resulted in an increase of p53 activity in
HepG2 cells treated with 5-ﬂuorouracil (5-FU).2. Materials and methods
2.1. Plasmids
Plasmids expressing wild-type HA (haemagglutinin)-tagged
p53 (pcDNA3/HA-p53) and mutants p53R248W (pcDNA-4TO-
p53HUR248W) and p53R273H (pcDNA-4TO-p53HUR273H) were
kindly provided by Dr. D. Kardassis (School of Medicine, University
of Crete, Heraklion, Greece) and Dr. W. Deppert (Heinrich-Pette-
Institut, Tumor Virology, Hamburg, Germany) respectively. To
express p53 as a GST fusion protein, p53 cDNA was digested with
EcoRI and BamHI from pcDNA3/HA-p53, repuriﬁed, and subcloned
into the BamHI and SmaI sites of pGEX-4T1 (Amersham Biosci-
ences). GFP-tagged SAFB1 (pGFP3-SAFB1) was kindly provided by
Dr. D. Elliott (Institute of Human Genetics, University of Newcastle,
Newcastle, UK). GST-SAFB1(1–240), GST-SAFB1(240–600) and
GST-SAFB2(641–953) were kindly provided by Dr S. Oesterreich
(Lester and Sue Smith Breast Center, Baylor College of Medicine,
Houston, TX, USA, see also [14]). GST-SAFB1(709–915) has been
previously described [15]. To construct pGEX-SAFB1(566–706)
the cDNA fragment coding for amino acids 566–706 of SAFB1
was ampliﬁed by PCR from pGFP3-SAFB1, using as primers: sense
50-CGCGGATCCATGGATAAATCCAAAGGGGTGCC-30 and antisense
50-CGGGAATTCCCGCTCCTGCTCATAGCGCAG-30, containing the
underlined BamHI and EcoRI sites respectively. The PCR fragment
was digested with BamHI and EcoRI, repuriﬁed and subcloned into
the BamHI and EcoRI sites of pGEX-4T1.
Plasmids encoding siRNAs targeting SAFB1were generated using
the siSTRIKE U6 Hairpin Cloning System (Promega). Brieﬂy, siSAFB1
encodes a siRNA targeting nucleotides 1739–1757 (50-GGACTGTA-
GTAATGGATAA-30) of the human SAFB1 mRNA (NM_002967.2),
while scrSAFB1 encodes a scrambled version of this sequence
(50-GAATGACTGATGAGATAGT-30) and was used as control. Both
the SAFB1 targeted and the control nucleotide were aligned against
the Genebank database sequences to ensure speciﬁcity. Plasmids
were puriﬁed using the Qiagen MaxiPrep protocol (Qiagen).
2.2. Cell culture and transfection
HepG2 and 293T cells were cultured in DMEM medium supple-
mented with 10% (v/v) fetal bovine serum (FBS) and antibiotics,
while K562 cells were maintained in RPMI medium plus 10% FBS
and antibiotics. HepG2 cells were treated with 50 lg/ml 5-FU or
200 nM mithramycin for 36 h, prior harvesting. 293T cells were
transfected using the calcium phosphate method as previously de-
scribed [16]. K562 cells were co-electroporated with the respective
constructs for transcription assays at 155 V and 1050 lF using the
Gene Pulser Xcell™ Electroporation System (Bio-Rad), according to
the manufacturer’s instructions. HepG2 cells were electroporated
with 20 lg of siSAFB1 or scrSAFB1 plasmid at 165 V and 1050 lFand then they were allowed to recover for 12 h before addition
of 2.3 lg/ml of puromycin. After three weeks of selection under
puromycin, cells were analyzed for SAFB1 expression and used in
transcription assays. HepG2 cells were transfected with the tran-
scription constructs using the calcium phosphate method.
2.3. Cell fractionation
Cell fractionation protocols were employed as described in [17].
Gel loading was adjusted to give equivalent cell numbers in each
lane.
2.4. GST pull-down and co-immunoprecipitation experiments
GST pull-down and co-immunoprecipitation experiments were
performed as previously described [16].
2.5. Transcription assays
Transcription assays were based on the ability of p53 to pro-
mote transcription of a (2325/+8) p21-CAT reporter gene in the
presence or absence of SAFB1. In K562 cells (p53 null cells) the
transfection mixture contained 2 lg of the (2325/+8) p21-CAT re-
porter plasmid, 3 lg of CMV b-gal plasmid, 0.5 lg of pcDNA3/HA-
p53 and when indicated increasing concentrations (1, 2 and 3 lg)
of pGFP3-SAFB1. In HepG2 cells (p53 positive cells) expressing
either scrSAFB1 or siSAFB1, the transfection mixture contained
2 lg of the (2325/+8) p21-CAT reporter plasmid and 3 lg of
CMV b-gal plasmid. In each case vector DNA was added as neces-
sary to achieve a constant amount of transfected DNA (15 lg). In
HepG2 cells 50 lg/ml 5-FU were added 12 h after transfection.
Forty eight hours post transfection both K562 and HepG2 cells
were harvested and CAT activities were determined using
14C-chloramphenicol and acetyl-CoA as previously described [18].
The results represent the mean of at least three independent trans-
fection experiments, each carried out in duplicate.
2.6. Immunoﬂuorescence microscopy
HepG2 cells seeded on coverslips were washed three times with
PBS. The samples were then ﬁxed with 1% formaldehyde in PBS,
permeabilized with 0.2% Triton X-100 and blocked with 0.5% ﬁsh
skin gelatin. Probing with the relevant primary [mouse monoclonal
anti-SAFB1 (Fbcam Inc.), diluted 1:150; rabbit polyclonal anti-p53
(FL-393, Santa Cruz), diluted 1:50] and secondary (FITC-conjugated
goat anti-mouse, diluted 1:400; RRX-conjugated goat anti-rabbit,
diluted 1:350) antibodies, was performed according to Maison
et al. [19].
2.7. Yeast two-hybrid screen
A yeast two-hybrid screen using as a bait a 528-bp fragment
coding for the NH2-terminal domain of SRPK1a (SRPK1aNt) was
performed as previously described [16].3. Results
3.1. SRPK1a interacts with SAFB1 and p53 in a yeast two-hybrid
system
SRPK1a is a much less studied alternatively spliced form of
SRPK1 that contains an insertion of 171 amino acids at its NH2-ter-
minal domain [16]. To isolate proteins that interact speciﬁcally
with SRPK1a a yeast two-hybrid screen was performed using as a
bait SRPK1aNt (encoding amino acids 1–176 of SRPK1a). Screening
Fig. 2. SAFB1 and p53 proteins co-immunoprecipitate from HepG2 cell extracts.
HepG2 cells were treated with 50 lg/ml 5-FU for 36 h, prior lysis. Immunoprecipi-
tations (1 mg of cell extract) were performed using either the anti-SAFB1
monoclonal antibody or the anti-p53 (DO-1) antibody. The bound proteins were
analyzed on 10% SDS-PAGE and immunoblotted with DO-1 (A) and anti-SAFB1 (B),
respectively. As control an irrelevant anti-GFP monoclonal antibody was used (ﬁrst
lane, in both A and B). A standard amount of cell extract, one-tenth of which is
shown, was used in each co-immunoprecipitaion assay.
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that remained positive for b-galactosidase activity when co-trans-
formed with the SRPK1aNt fusion protein but not with the DNA
binding domain of GAL4 alone. As previously described, three of
the positive clones that showed the strongest interaction, were dif-
ferent isolates of SAFB1 [16]. Proceeding with the characterization
of the remaining positive clones, we noticed that two clones, show-
ing weaker interaction than SAFB1, encoded p53. On the basis of
the p53 sequences isolated by the two-hybrid screen, COOH-termi-
nal residues 254–390 of p53 (accession number Q549C9) appear to
be sufﬁcient for the interaction with SRPK1aNt. The observed inter-
action seems to be speciﬁc, because both p53 clones showed a very
weak interaction with SRPK1 (Supplementary Fig. 1A).
Using pull-down assays we conﬁrmed that FLAG-SRPK1a over-
expressed in 293T cells was able to interact with GST-p53
in vitro (Supplementary Fig. 1B). The interaction of SRPK1a with
p53 was further demonstrated in vivo by co-immunoprecipita-
tion/Western blotting analysis (Supplementary Fig. 1C).
3.2. p53 interacts and partially co-localizes with SAFB1 in HepG2 cells
treated with 5-FU or mithramycin
Given that both SAFB1 and p53 were shown to interact with
SRPK1a and that a fraction of nuclear p53 was previously found
associated with the nuclear matrix [5], we sought to investigate
whether there is an interaction between SAFB1 and p53. In this re-
spect it should be noted that neither SAFB1 nor p53 contain an RS
domain and consequently they are not phosphorylated by SRPKs
(data not shown). As a ﬁrst step, we studied the subcellular distri-
bution of endogenous p53 and SAFB1 in HepG2 cells by biochem-
ical fractionation. HepG2 cells have been used in the past as a
model system to study p53 because they express a wild-type p53
protein that can be activated to elicit normal p53 function
[20,21]. Under normal conditions of growth, p53 protein was al-
most equally distributed between the cytoplasm and the nucleus,
while only a minimal amount of p53 was found associated with
the nuclear matrix fraction (Fig. 1A). SAFB1 was exclusively nucle-
ar. A sub-population of SAFB1 molecules was soluble and detected
in the nucleoplasmic fraction, while the majority of SAFB1 protein
was found associated with the nuclear matrix (Fig. 1A).
To test whether the distribution of SAFB1 and p53 could be
modulated by treatment of cells with genotoxic agents, HepG2
cells were treated with 50 lg/ml 5-FU or 200 nM mithramycinFig. 1. Distribution of endogenous p53 and SAFB1 proteins between different
subcellular compartments following biochemical fractionation. HepG2 cells were
harvested and the nuclei separated from the cytoplasmic fraction. Puriﬁed nuclei
were isolated by passing the crude nuclear fraction through a sucrose cushion and
subjected to sequential extraction steps (for pertinent information see Ref. [5]), to
yield a nucleoplasmic fraction, a DNAse I extract fraction and a DNAse I resistant
nuclear pellet that is designated the nuclear matrix. The p53 and SAFB1 proteins
were detected by immunoblotting using a mouse monoclonal anti-p53 (DO-1) and
a mouse monoclonal anti-SAFB1 respectively. (A) HepG2 cells grown under normal
conditions, (B) HepG2 cells treated with 50 lg/ml 5-FU for 36 h, prior to
fractionation. A similar distribution was observed when cells were treated with
200 nM mithramycin instead of 5-FU (data not shown).for 36 h, prior to fractionation. The rationale for choosing these
two drugs was that 5-FU and mithramycin are both known to
upregulate p53 but through different mechanisms. More speciﬁ-
cally, 5-FU inhibits the cell’s ability to synthesize properly DNA
and RNA, while mithramycin interferes with the transcription of
genes that bear GC-rich motifs in their promoters. As shown in
Fig. 1B, the distribution pattern of SAFB1 was unaffected, whereas
as expected, both drugs induced an increase in the total amount of
cellular p53. The increase was far more pronounced in the nuclear
fraction. Roughly equivalent amounts of p53 were detectable in the
nucleoplasmic and nuclear matrix fractions (Fig. 1B).
Following these observations, we next asked whether native
cellular SAFB1 and p53 proteins interact with each other in HepG2
cells treated with 50 lg/ml 5-FU for 36 h. Fig. 2A shows that an
anti-SAFB1 antibody can immunoprecipitate p53 from HepG2 cells
(left panel), while the anti-p53 monoclonal antibody DO-1 was
also able to immunoprecipitate SAFB1 (right panel), but less
efﬁciently.Fig. 3. The C-terminal region of SAFB1 interacts with p53. (A) Schematic presen-
tation of full-length SAFB1 and of the deletion constructs used for mapping the
SAFB1–p53 interaction region. The characteristic domains of SAFB1 are also
illustrated in the top diagram. (B) SDS–PAGE analysis and Coomassie Blue staining
of the puriﬁed GST-fusion proteins encoding different regions of SAFB1. (C) GST
pull-down assays employing 293T cell extracts overexpressing p53 and GST–fusion
proteins as indicated. Bound p53 was detected with the DO-1 monoclonal antibody.
A standard amount of cell extract, one-tenth of which is shown, was used in each
binding assay.
Fig. 4. Localization of endogenous p53 and SAFB1 in control and 5-FU treated
HepG2 cells. Patterns of SAFB1 and p53 in control (upper panel), and in 5-FU-
treated (lower panel) HepG2 cells. The specimens were doubly stained with mouse
monoclonal anti-SAFB1 (FITC, green) and rabbit polyclonal anti-p53 (RRX, red).
Colocalization of SAFB1 and p53 in nuclear speckles in 5-FU treated cells (merge) is
indicated by arrows.
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the region in SAFB1 mediating this interaction. To this end we
generated a series of GST-SAFB1 deletion constructs (Fig. 3A),
and conﬁrmed the correct protein expression (Fig. 3B). Performing
GST-pull down assays with the N-terminal (aa 1–260), central (aaFig. 5. Overexpression of SAFB1 inhibits the transcriptional activity of p53 in p53-null
different subcellular compartments in K562 cells. K562 cells were co-transfected with 0
performed as in Fig. 1. The p53 and SAFB1 proteins were detected by immunoblotting u
were transiently transfected with the (2325/+8) p21-CAT construct (2 lg) along with
indicated beneath each histogram. The CMV b-gal plasmid (3 lg) was included in each sa
three independent experiments. (C) Thirty micrograms of the indicated transcription extr240–600), Glu/Arg rich (aa 566–706) and C-terminal (aa 709–915)
regions of SAFB1 and 293T cell extracts overexpressing HA-p53, we
identiﬁed the C-terminal region of SAFB1 as the p53-interacting
domain (Fig. 3C).
To further analyze the localization and interaction between
SAFB1 and p53 we performed confocal microscopy co-localization
studies (Fig. 4). Under normal conditions of growth, p53 dispersed
throughout the cytoplasm and the nucleus of HepG2 cells with no
apparent co-localization with SAFB1. Treatment of HepG2 cells
with 5-FU resulted in a signiﬁcant increase of the nuclear concen-
tration of p53 and a clearly visible co-localization with SAFB1 in
several nuclear speckles.
As the mouse monoclonal anti-SAFB1 antibody used in the
co-immunoprecipitation and immunoﬂuorescent experiments of
this study may also target SAFB2, a highly related family member
of SAFB1 [22], we tested whether the interaction of p53 with SAFB1
was speciﬁc or a similar interaction may also occur with SAFB2.
GST-pull down assays employing the C-terminal regions of SAFB1
and SAFB2 (GST-SAFB1(709–915) andGST-SAFB2(641–953) respec-
tively) and 293T cell extracts overexpressing HA-p53 showed that
both SAFB proteins may interact with p53 (Supplementary Fig. 2).
Interestingly, there have been some previous reports that
certain p53 mutants, containing DNA contact mutations, interact
stronger with the nuclear matrix, and especially the S/MAR
elements of DNA, than the wild-type protein [23,24]. We tested
two such p53 mutants, p53R273H, that was used in the previouscells. (A) Distribution of exogenously expressed p53 and SAFB1 proteins between
.5 lg of pcDNA3/HA-p53 and 2 lg of pGFP3-SAFB1. Biochemical fractionation was
sing the DO-1 and the anti-SAFB1 monoclonal antibody respectively. (B) K562 cells
p53 (0.5 lg) in the absence or presence of increasing concentrations of SAFB1 as
mple for normalization of transfection variability. Data represent the means ± SE of
acts were analyzed on 12% SDS–polyacrylamide gels and immunoblotted with DO-1.
Fig. 6. Knock-down of SAFB1 potentiates the transcriptional activity of p53 in
HepG2 cells treated with 5-FU. HepG2 cells expressing either scrSAFB1 or siSAFB1
were transfected with the (2325/+8) p21-CAT and the CMV b-gal plasmids. Cells
were collected 48 h post transfection and cell extracts were prepared as previously
described [15]. When indicated 50 lg/ml 5-FU were added 12 h after transfection
and cells were collected 36 h later. (A) Thirty micrograms of cell extracts were
analyzed on 12% SDS–polyacrylamide gels and immunoblotted with the anti-SAFB1
and the DO-1 monoclonal antibody respectively. The protein levels of SAFB1 are
shown only in untreated HepG2 cells. A similar pattern was observed when cells
were treated with 5-FU (data not shown). (B) Cell extracts were tested for their
transcriptional activity towards the (2325/+8) p21-CAT reporter gene. Data
represent the means ± SE of three independent experiments.
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with SAFB1. As shown in Supplementary Fig. 3, p53R248W was
able to interact with the C-terminal domain of SAFB1 with the
same efﬁciency as wtp53, while the p53R273H/SAFB1 interaction
was weaker.
3.3. Repression of p53-dependent transcription by SAFB1
Given that p53 functions as a gene-speciﬁc transcriptional acti-
vator, we investigated whether SAFB1 has any effect on the tran-
scriptional activity of p53. To this end we initially used K562
cells that do not express p53 and a p21 promoter-containing CAT
reporter system. p21(WAF1/CIP1) is a major transcriptional target
of p53 and it plays a critical role in p53-dependent cell cycle arrest
[25]. An advantage of using the p53-null K562 cell line was that
exogenously expressed p53 exhibited a subcellular distribution
pattern similar to the one observed in 5-FU-treated HepG2 cells
(Fig. 5A, left panel). Compared to cells transfected with p53 alone,
cells co-transfected with p53 and SAFB1 exhibited a 0.2–4-fold de-
crease in CAT activity, depending on the concentration of SAFB1
(Fig. 5B). Since SAFB1 was proposed to function as a more general
transcriptional inhibitor [12,13] and therefore overexpression of
SAFB1 could result in smaller amounts of p53 protein synthesized
from the expression plasmid which would itself result in decreased
CAT activity, we performed Western blotting analysis of p53 from
the cell extracts that were used in the transcription assays. As
shown in Fig. 5C SAFB1 did not affect the protein levels of p53.
The functional signiﬁcance of the SAFB1-p53 interaction was
further demonstrated by knocking-down SAFB1 in HepG2 cells.
To this end HepG2 cells were electroporated with 20 lg of siSAFB1
or scrSAFB1 and after three weeks of selection under puromycin
they were used in transcription assays, in the absence and pres-ence of 50 lg/ml 5-FU. The reduced protein levels of SAFB1 were
conﬁrmed by Western blotting (Fig. 6A, left panel), while the pro-
tein levels of p53 remained unaffected upon expression of siSAFB1
(Fig. 6A, right panel). As shown in Fig. 6B, the activity of the p21
reporter, in the absence of 5-FU, was practically not affected upon
treatment with siSAFB1. This is reasonable taking into consider-
ation that in the absence of 5-FU a minimal co-localization of
SAFB1 and p53 is observed. In the presence of 5-FU, knock-down
of SAFB1 resulted in a 3.5-fold increase of CAT activity, further
conﬁrming the role of SAFB1 as a transcriptional repressor of p53.4. Discussion
The tumor suppressor p53 regulates cell cycle progression and
apoptosis in response to various types of stress, whereas excess
p53 activity creates unwanted effects. Therefore, tight regulation
of p53 is essential for maintaining normal cell growth. In addition,
a tight regulation of p53 is required following stress response. As in
unstressed cells, the activity of p53 needs to be precisely adjusted
once the cellular machinery has counteracted the stress. The prin-
cipal mechanisms governing p53 activity appear to be exerted at
the protein level. These include regulation of p53 stability, post-
translational modiﬁcations and conformational changes that con-
trol the DNA binding activity of p53 [26]. The central component
in p53 regulation is the p53-interacting protein MDM2/HDM2
[27]. Binding of MDM2 to p53 inhibits p53’s transcriptional activ-
ity. In addition MDM2 is a RING-ﬁnger protein that functions as a
ubiquitin ligase for p53, leading to its proteosomal degrada-
tion.p53 degradation occurs mainly on cytoplasmic proteasomes
and, hence, has an absolute requirement for nuclear export of
p53 via the CRM1 pathway [28]. Yet, cytoplasmic export of ubiqui-
tinated p53 is relatively slow and consumes signiﬁcant energy in
the form of Ran-GTP for the CRM1 pathway [29]. Accumulating
evidence suggest that p53 levels and activity may also be regulated
inside the nucleus and that the nuclear matrix is actively involved
in this regulation, either positively or negatively.
More speciﬁcally, the interaction of certain p53 mutants with
the S/MAR elements of DNA resulted in gain of function that was
proposed to result through the reorganization of chromatin and
the recruitment of speciﬁc transcriptional complexes on these ele-
ments [24]. On the other hand, SMAR1, a nuclear matrix-associated
protein that, like SAFB proteins, interacts with MARs (Matrix
Attachment Regions), was reported to form a ternary complex with
MDM2-p53 and negatively regulate p53-mediated transcription
[30]. In addition, P2P-R (also known as PACT and Rbbp6), a
hnRNP-related protein that interacts with SAFB1, was recently
shown to interact with HDM2 and enhance HDM2-mediated ubiq-
uitination and degradation of p53 as a result of the increase of the
p53–HDM2 afﬁnity [31–33]. SAFB1 (and potentially SAFB2) further
expands the list of nuclear matrix-associated proteins that nega-
tively regulate p53 activity. This function of SAFB1 is consistent
with previously published evidence documenting that SAFB1
may function as transcriptional repressor via its C-terminal
domain, the same region that was shown to interact with p53
[11–14]. An intriguing speculation based on these data is that there
may be various nuclear matrix-binding sites for p53 that ﬁne-tune
its activity. For example the R273 mutation may potentiate the
binding of p53 to S/MAR elements resulting in gain of function
[23,24], whereas the same mutation reduces the afﬁnity of p53
for SAFB1 (Supplementary Fig. 3, this study).
The SAFB1-mediated down-regulation of p53 is most likely part
of a feedback mechanism functioning only under stress conditions,
since the amount of p53 associated with SAFB1 without the
addition of genotoxic agents (see Figs. 1 and 4) is practically
negligible. In this respect the inactivation of p53 by SAFB1 is not
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results in increased proliferation [13,34]. It is also interesting to
note that SAFB proteins have been shown to inhibit proliferation
mainly through repression of nuclear receptors and particularly
the estrogen receptor [12,22]. Given the opposing roles of ER and
p53 (with ER promoting cell proliferation and p53 slowing it
down) but also their functional interactions [35,36] an additional
interesting hypothesis is that SAFB proteins may ﬁne tune the mu-
tual transcriptional silencing of these two molecules, thus regulat-
ing cell growth. When the cells need to proliferate SAFB would
inhibit the cell growth suppressive functions of p53 and release
ER, whereas when the cells need to stop proliferating SAFB would
shift towards inhibiting the expression of ER responsive genes and
releasing p53. This shift could be mediated through the ability of
SAFB1 to participate in different transcription regulatory com-
plexes associated with the nuclear matrix [8,9].
Such complexes are probably transiently formed inside the nu-
cleus [37]. Depending on the cellular activities, a fraction of nuclear
SRPKs may be recruited to speciﬁc SAFB-complexes and inacti-
vated by interacting with SAFB molecules [15]. The inhibition of
RS domain-dependent phosphorylation may affect the composition
of these transient complexes per se, since various SAFB partners
contain RS domains, thus inﬂuencing gene transcription and/or
mRNA splicing [38]. For example, P2P-R was shown to be a
substrate or SRPK1a [39], while ZO-2, another SAFB1 interacting
protein that was shown to inhibit proliferation through downreg-
ulation of cyclin D1 [40,41], also contains an RS domain and may
be targeted by SRPKs. In this respect, elucidating the structure
and the molecular mechanisms governing the assembly of nuclear
matrix-associated complexes will unravel important information
concerning the regulation of the transcriptional machinery.
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